Category REGENERATIVE MEDICINE

Wyss Institute researchers demonstrate machine-guided engineering of AAV capsids for gene therapy

High-throughput synthetic biology approach reveals hidden AAV features and could help fast-track future gene therapies Adeno-associated viruses (AAVs) have become the go-to vehicle for delivering therapeutic gene cargo to target tissues for the wave of gene therapies that are in development in academic and biotechnology laboratories. However, natural AAVs do not specifically target diseased cells

Read More


BIOLOGICS ALLIANCE™ INITIATES COLLABORATION WITHIN ORTHOPAEDICS COMMUNITY

For the first time, The Arthroscopy Association of North America (AANA), the American Orthopaedic Society for Sports Medicine (AOSSM), the International Cartilage Repair Society (ICRS) and the ON Foundation have collaborated to form The Biologics Alliance (BA)™, an orthopaedic organization dedicated to providing one voice for all matters on musculoskeletal biologics and regenerative medicine. Recently, randomized clinical trials and clinical practice guidelines

Read More


Investment in UK cell and gene therapy manufacturing set to continue

New data released shows cell and gene therapy manufacturing facilities are rapidly becoming operational reflecting job expansion in the sector. Additional 6,000m2 of cell and gene therapy manufacturing space expected to become available within the next 12 months. The Cell and Gene Therapy Catapult (CGT Catapult) published the sixth annual UK cell and gene therapy

Read More


Wnt Signaling in 3D: Recent Advances in the Applications of Intestinal Organoids

Using organoid technology, adult epithelial stem cells can be expanded in vitro to generate self organizing 3D epithelial structures that closely recapitulate the architecture and cellular composition of the tissue of origin. Because of their strict dependence on Wnt ligands for survival and growth, intestinal organoids have become the tool of choice for in vitro

Read More


University of Miami Initiates CAR-T Clinical Trial in Myasthenia Gravis

Neuromuscular experts with the University of Miami Health System and the Miller School of Medicine will launch a Phase 1/2 clinical trial (NCT04146051) using the CAR-T drug, Descartes-08, to treat patients with generalized myasthenia gravis. Generalized myasthenia gravis (GMG) is a rare disease and a chronic autoimmune condition in which auto-antibodies attack specific proteins at the

Read More


A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro

Purpose: The primary goal of the present study was to develop the nano-drug consisting of doxorubicin and exosome derived from mesenchymal stem cells, and to explore its effect on osteosarcoma in vitro. Methods: The exosomes were isolated from bone marrow MSCs (BM-MSCs) by an Exosome Isolation Kit. The exosome-loaded doxorubicin (Exo-Dox) was prepared by mixing

Read More


Moffitt Researchers Identify a Mechanism Controlling Tumor Cell Recognition by Immune Cells

Immunotherapy has become a standard treatment approach for several types of cancer, including melanoma. However, tumors can escape immune cell detection even with the use of immunotherapies. In a new study published in Cancer Immunology Research, Moffitt Cancer Center researchers, in collaboration with the University of Miami’s Miller School of Medicine, describe a cellular mechanism that controls tumor cell

Read More


The Alliance for Regenerative Medicine Outlines Recommendations for Increasing the Number of European-Based ATMP Clinical Trials

Europe has become less competitive than other regions in attracting new ATMP clinical trials. Faster and more streamlined review processes for clinical trials by regulatory authorities are fundamental to increase clinical research and development in Europe. There is considerable country-to-country variability within Europe: the UK has the highest absolute number of new ATMP clinical trials,

Read More